Key Drivers
- Strong Liquidity
- Improving Cash Flow
- High Leverage
AIAI Summary
ALNY has evolved from a pure RNAi growth story into a proof-of-execution trade, where durable Amvuttra demand and credible guidance reacceleration must offset a still-rich valuation and legal overhang, so near-term upside now depends on clean commercial follow-through rather than platform optionality alone.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Improving Cash Flow
- •High Leverage
ALNY shows improving cash generation and strong liquidity, but its leveraged balance sheet and very rich valuation limit upside.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Gap-down damage
- •Overhead supply
ALNY has stabilized over the last month with higher lows and higher highs, but it remains below the post-breakdown range and faces key resistance near $228.65 and $266-$289.
Sharp gap-down decline from the $205.5 breakdown area signals volatility risk
Sentiment & News
Key News Insights:
- •Revenue Surge
- •Guidance Cut
- •Fraud Scrutiny
Alnylam delivered strong Q2 revenue growth driven by Amvuttra, but an earnings miss, lowered sales outlook, and mounting securities-fraud investigations sent the stock sharply lower.
The combination of weaker-than-expected results and legal overhang is likely to keep pressure on ALNY shares and investor sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings